Database for predicting cancer treatment response to cytokine therapy
Open Prospective Observational Cohort Study of the Effectiveness and Safety of Cytokinogenetic Therapy in Patients With Cancer Based on TCTD-1 Patient Registry
This study is trying to build a database to see how well cytokine therapy works for adults with cancer and what factors might influence their treatment outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years to 95 Years |
| Sex | All |
| Sponsor | OncoCareClinic 308 Ltd Academic / other |
| Locations | 1 site (Moscow) |
| Trial ID | NCT06222801 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a comprehensive database to analyze the effectiveness and safety of cytokine therapy in cancer patients. It will collect extensive demographic, clinical, radiological, genetic, and laboratory data over a 10-year period to identify key factors influencing treatment outcomes. The study will focus on adult patients diagnosed with neoplasia who are eligible for cytokine therapy, aiming to develop and validate a predictive model for treatment response. By understanding the relationship between initial patient characteristics and therapy effectiveness, the study seeks to personalize treatment strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients aged 18 years or older with a cancer diagnosis who are eligible for cytokine therapy.
Not a fit: Patients under 18 or over 95 years, those with hematologic cancers or thyroid tumors, and those with contraindications for cytokine therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for cancer patients undergoing cytokine therapy.
How similar studies have performed: While the approach of creating a predictive database is innovative, similar studies have shown promise in improving treatment personalization in oncology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * adult patients aged 18 years or older with cancer who do not meet exclusion criteria, applied to the OncoCare308 Clinic Ltd. hospital for cytogenetic therapy, and are eligible to complete or have completed at least one course of cytogenetic therapy, as determined by the site. Exclusion Criteria: * Patients under 18 or over 95 years * Patients with hematologic cancer or thyroid tumors * Patients with contraindications for cytogenetic therapy * Patients who die before the start of therapy or before the first course completeness * Patients who do not sign the informed consent to be enrolled under the clinical observation in the hospital
Where this trial is running
Moscow
- OncocareClinic 308 — Moscow, Russia (Recruiting)
Study contacts
- Study coordinator: Artem L Kornilov, Master
- Email: info@oncocareclinic.ru
- Phone: 8107 (499) 322 23 08
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.